BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

The investigational injection fosgonimeton appeared to have better efficacy in patients with more severe disease, according ...

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported ...

Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli ...

Analysts expect the companies’ Eylea HD and Vabysmo to generate $13.2 billion between them by 2030 in the vascular ...

Getting caught between younger team members and older bosses can be stressful for millennial managers. A leadership expert ...

The intellectual property landscape for newer gene-editing technologies, like that for CRISPR-Cas9, remains unclear and hard ...

Eli Lilly offers weight loss drug Zepbound directly to consumers while Novo Nordisk continues to struggle with supply ...

Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North ...

With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could ...

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in ...